Stryker’s LFIT V40 Femoral Head lawsuits continue to move forward: 4 takeaways

Hip replacement lawsuits surrounding Stryker’s LFIT Anatomic CoCr V40 Femoral Head components moved forward to the U.S. District Court, District of Massachusetts.

Advertisement

Here are four takeaways:

 

1. A Scheduling Order indicated the proceeding’s first bellwether trial will begin on Sept. 16, 2019. Bellwether case specific discovery may begin Feb. 8, 2017.

 

2. Documents have indicated at least 99 Stryker hip lawsuits involving LFIT V40 femoral heads are pending in the District of Massachusetts. Additional claims have been consolidated in New Jersey’s Bergen County Superior Court.

 

3. Many of the pending cases involve specific LFIT V40 femoral heads that were included in Stryker’s hip recall in August 2016. The affected components had been associated with a higher number of complaints involving taper lock failure.

 

4. The recall was designated as a Class II medical recall by the FDA in November 2016. A Class II designation “indicates that a device may cause temporary or medically reversible adverse health consequences.”

 

More articles on devices and implants:
Xtant Medical postpones Q3 2017 financial results release: 3 insights
3 NASS presentations highlight evidence for lumbar total disc replacement
Safe Orthopaedics names François-Henri Reynaud new chief financial, administrative officer — 3 notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.